CLLS - セレクティス (Cellectis S.A.) セレクティス

 CLLSのチャート


 CLLSの企業情報

symbol CLLS
会社名 Cellectis SA (セレクティス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS) used for gene excision correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field in pharmaceutical drug discovery programs in the agronomics bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States among others.   セレクティスは、フランスのゲノム工学会社。独自のコア技術を採用し、免疫腫瘍学の分野で製品を開発する。同社の製品には、B細胞悪性腫瘍などのCD19を有する細胞を標的とし殺傷することのできるT細胞製品のUCART19がある。また、製品の候補には、UCART123、UCARTCS1、UCART38などがある。   
本社所在地 8 rue de la Croix Jarry Paris 75013 FRA
代表者氏名 Andre Choulika アンドレ・チュリカ
代表者役職名 Chairman of the Board Chief Executive Officer Member of the Executive Board
電話番号 +33 1-8169-1600
設立年月日 36526
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 135人
url www.cellectis.com
nasdaq_url https://www.nasdaq.com/symbol/clls
adr_tso 16101659
EBITDA EBITDA(百万ドル) -99.62027
終値(lastsale) 27.45
時価総額(marketcap) 441990539.55
時価総額 時価総額(百万ドル) 1121.578
売上高 売上高(百万ドル) 30.85860
企業価値(EV) 企業価値(EV)(百万ドル) 631.49400
当期純利益 当期純利益(百万ドル) -85.63750
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cellectis SA (ADR) revenues decreased 15% to $16.4M. Net loss decreased 30% to $32.4M. Revenues reflect Revenues decrease of 16% to $11.1M Other income decrease of 12% to $5.3M. Lower net loss reflects Financial expenses decrease of 74% to $3M (expense) Financial Income increase from $4.7M to $13M (income) Research and development expenses decrease of 5% to $36.4M (expense).

 CLLSのテクニカル分析


 CLLSのニュース

   ADRs End Lower, BRF SA, Cellectis SA Trade Actively - Morningstar  2022/04/29 00:01:14 Morningstar
ADRs End Lower, BRF SA, Cellectis SA Trade Actively Morningstar
   Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut  2022/04/27 16:51:41 Benzinga
About 14 months after inking a natural killer cell deal with Cellectis SA (NASDAQ: CLLS ), Cytovia plans to list on NASDAQ via a merger with the SPAC Isleworth Healthcare Acquisition Corp (NASDAQ: ISLE ). The company went on to create a China joint venture. The biotech teamed up with China-based biotech investor TF Capital to form CytoLynx … Full story available on Benzinga.com
   Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics  2022/04/27 06:44:00 Wallstreet:Online
Cellectis is developing custom TALEN for Cytovia to develop gene-edited iPSC-derived Natural Killer cells Cytovia and Isleworth Healthcare Acquisition Corp. announce business combination agreement and combined company is expected to be listed on NASDAQ under the ticker symbol INKC $20 million note represents upfront collaboration consideration and would convert into
   Cellectis Reveals Preclinical Data On First Allogeneic Dual CAR T-Cell Product In Non-Hodgkin Lymphoma  2022/04/11 16:15:17 Benzinga
Cellectis SA (NASDAQ: CLLS ) released preclinical data on its product candidate UCART20x22 at the American Association for Cancer Research (AACR) Annual Meeting. The Company said that the data showed preclinical proof of concept with the potential to overcome common mechanisms of resistance to CAR T-cell therapies in relapsed or refractory Non-Hodgkin Lymphoma … Full story available on Benzinga.com
   What Analysts Were Expecting After Cellectis S.A. (NASDAQ: CLLS) rose 6.83%  2022/04/02 16:00:00 Stocks Register
Cellectis S.A. (NASDAQ:CLLS) shares, rose in value on Friday, 04/01/22, with the stock price up by 6.83% to the previous day’s close as strong demand from buyers drove the stock to $4.85. Actively observing the price movement in the last trading, the stock closed the session at $4.54, falling within a range of $4.51 and … What Analysts Were Expecting After Cellectis S.A. (NASDAQ: CLLS) rose 6.83% Read More »
   What Analysts Were Expecting After Cellectis S.A. (NASDAQ: CLLS) rose 6.83%  2022/04/02 16:00:00 Stocks Register
Cellectis S.A. (NASDAQ:CLLS) shares, rose in value on Friday, 04/01/22, with the stock price up by 6.83% to the previous day’s close as strong demand from buyers drove the stock to $4.85. Actively observing the price movement in the last trading, the stock closed the session at $4.54, falling within a range of $4.51 and … What Analysts Were Expecting After Cellectis S.A. (NASDAQ: CLLS) rose 6.83% Read More »
   Cellectis (CLLS) Investor Presentation - Slideshow  2022/03/25 18:13:38 Seeking Alpha
   Analysts Say That Cellectis S.A. (NASDAQ:CLLS) Is Likely To Make It To $38.00 In 12 Months  2022/03/19 15:00:00 Marketing Sentinel
In last trading session, Cellectis S.A. (NASDAQ:CLLS) saw 0.88 million shares changing hands with its beta currently measuring 2.23. Company’s recent per share price level of $4.06 trading at -$0.6 or -12.88% at ring of the bell on the day assigns it a market valuation of $196.99M. That closing price of CLLS’s stock is at … Analysts Say That Cellectis S.A. (NASDAQ:CLLS) Is Likely To Make It To $38.00 In 12 Months Read More »
   Catalent Appoints Frederic Cedrone as Vice President, Corporate Innovation  2022/03/17 15:45:00 Benzinga
SOMERSET, N.J. , March 17, 2022 /PRNewswire-PRWeb/ -- Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the appointment of Frederic Cedrone , Ph.D., as Vice President, Corporate Innovation. Dr. Cedrone will collaborate closely with Catalent''s scientific teams and external partners to leverage innovative technologies in the development of emerging therapeutic modalities. Dr. Cedrone brings with him more than 25 years of experience in biologic drug development, including cell and gene therapies, and joins Catalent from Lysogene SA in Paris, France , where he held the role of Vice President, Alliances & Business Development. Prior to Lysogene, Dr. Cedrone worked at Cellectis SA, where he held a number of senior roles, both as a scientist … Full story available on Benzinga.com
   Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers  2022/03/16 13:21:32 Benzinga
The FDA has signed off Iovance Biotherapeutics Inc''s (NASDAQ: IOVA ) Investigational New Drug Application (IND) first genetically modified TIL therapy, IOV-4001, for unresectable or metastatic melanoma and stage III or IV non-small-cell lung cancer (NSCLC). IOV-4001 leverages the gene-editing TALEN technology licensed from Cellectis SA (NASDAQ: Full story available on Benzinga.com
   TCR-based Therapies Market Skyrocketing $4 Bn by 2028| Autolus, bluebird bio, CARsgen Therapeutics, Celgene, Cell Medica, Cellectis, Cellular Biomedicine Group, Immunocore, Innovative Cellular Therapeutics, Kite Pharma, Lion TCR, ZIOPHARM Oncology  2021/09/10 11:19:27 OpenPR
TCR-based Therapies Market is projected to reach at $4 Bn at a CAGR +13% by the time lapse of 2021-28. TCR-based Therapies involves treating cancer with activated T lymphocytes from the body. Both strategies attach new receptors to the cells'' surfaces,
   Cellectis Announces Participation in Five Investor Conferences  2021/08/26 20:34:00 Intrado Digital Media
NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS EURONEXT GROWTH: ALCLS) (the Company), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for monogenic diseases, today announced that management plans to participate in five virtual investor conferences.
   T-Cell Immunotherapy Market Set for Rapid Growth and Trend by 2021-2027 | Cellectis, Takara Bio  2021/08/18 07:47:15 OpenPR
This informative T-Cell Immunotherapy market report covers small bunch of information for a scope of period including from 2021 to 2027. This figure ends up being exceptionally gainful for the forthcoming business sector business people. This information in a factual
   Cellectis S.A. (CLLS) CEO André Choulika on Q2 2021 Results - Earnings Call Transcript  2021/08/06 19:33:04 Seeking Alpha
   Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021  2021/08/05 20:30:00 Intrado Digital Media
Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed or refractory multiple myeloma patients.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セレクティス CLLS Cellectis S.A.)

 twitter  (公式ツイッターやCEOツイッターなど)